A novel approach for the purification of biopharmaceuticals using polymer-based aqueous biphasic systems with ionic liquids as adjuvants

Biopharmaceuticals are therapeutic drugs produced via biotechnological processes currently applied in the treatment of life-threatening diseases, representing a fast-growing area with an estimated market of $100 billion in 2017. Among these is interferon alfa 2b (IFNα-2b), a protein with significant...

ver descrição completa

Detalhes bibliográficos
Autor principal: Castro, Leonor S. (author)
Outros Autores: Pereira, Patrícia (author), Passarinha, Luís A. (author), Freire, Mara G. (author), Pedro, Augusto Q. (author)
Formato: conferenceObject
Idioma:eng
Publicado em: 2020
Assuntos:
Texto completo:http://hdl.handle.net/10773/29921
País:Portugal
Oai:oai:ria.ua.pt:10773/29921
Descrição
Resumo:Biopharmaceuticals are therapeutic drugs produced via biotechnological processes currently applied in the treatment of life-threatening diseases, representing a fast-growing area with an estimated market of $100 billion in 2017. Among these is interferon alfa 2b (IFNα-2b), a protein with significant antiviral and immunomodulatory activities currently applied in the treatment of oncological diseases. Although significant advances at the upstream level have been faced, current purification strategies are unable to cope with high product concentrations in a cost-effective approach. In this work, it was developed a cost-effective technology for the purification of IFNα-2b from Escherichia coli BL21 cultures, using polymer-polymer based aqueous biphasic systems (ABS) with ionic liquids (ILs) as adjuvants. Enhancements up to 3.5 in IFNα2b purification factors without affecting the IFNα2b structure were achieved in presence of ILs.